CheckMate 816 — neoadjuvant nivolumab plus chemotherapy¶
One-paragraph summary¶
CheckMate 816 randomized resectable stage IB–IIIA NSCLC to three cycles of neoadjuvant nivolumab plus platinum-doublet chemotherapy or chemotherapy alone before planned surgery. The combination improved event-free survival (EFS) and pathological complete response (pCR), increased the proportion proceeding to surgery, and did not increase grade 3–4 treatment-related adverse events. It established a neoadjuvant-only immune strategy without a mandated postoperative checkpoint component.
Quantitative findings¶
| Outcome | Nivolumab + chemotherapy | Chemotherapy | Effect |
|---|---|---|---|
| Median EFS | 31.6 months | 20.8 months | HR 0.63 (97.38% CI 0.43–0.91) |
| pCR | 24.0% | 2.2% | OR 13.94 |
| Underwent surgery | 83.2% | 75.4% | Higher with combination |
| Grade 3–4 treatment-related adverse events | 33.5% | 36.9% | No increase |
Long-term update¶
Final OS analysis reported a death HR of 0.72 (95% CI 0.523–0.998) and estimated five-year OS of 65.4% versus 55.0% ([PMID 40454642](https://pubmed.ncbi.nlm.nih.gov/40454642/){target="_blank" rel="noopener"}). Five-year OS was 95.3% among patients with pCR versus 55.7% without; presurgical ctDNA clearance was also associated with better OS. Those are response associations, not randomized validation of treatment changes based on pCR or ctDNA.
LUSC relevance¶
The trial included squamous and non-squamous NSCLC and used histology-compatible platinum partners. Subgroup consistency supports LUSC use, but absolute LUSC-specific benefit and biomarker interactions are less precise than the overall result. Central anatomy can also make surgery and radiographic response harder to interpret.
Limitations¶
- Open-label treatment assignment.
- Stage definitions and eligibility do not map perfectly to ninth-edition groups.
- Patients with known EGFR/ALK alterations were a small/special context; modern guidelines apply driver exclusions.
- pCR processing requires standardized pathology.
- The trial does not answer whether perioperative adjuvant checkpoint therapy adds benefit after the same neoadjuvant regimen.
Why it matters¶
CheckMate 816 moved immunotherapy into curative-intent resectable NSCLC and proved that short preoperative exposure can improve both pathological and time-to-event outcomes without reducing surgical delivery. It is the key comparator for longer perioperative strategies.
Cited by wiki pages¶
- Overview
- Early-stage and perioperative therapy
- Guidelines
- Clinical-trials landscape
Verified citation¶
Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985. [PMID 35403841](https://pubmed.ncbi.nlm.nih.gov/35403841/){target="_blank" rel="noopener"}